SCHEMBL2828599

SCHEMBL2828599

Clc1cccc2c1CCO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 1/20 0.42
ICAM1 P05362 1/20 0.42
ITGAL P20701 1/20 0.42
P2RX7 Q99572 1/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 2/20 0.38
CRHBP P24387 2/20 0.38
CRHR2 Q13324 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
EED O75530 1/20 0.38
SUZ12 Q15022 1/20 0.38
EZH2 Q15910 1/20 0.38
AHR P35869 1/20 0.38
ADRA2A P08913 2/20 0.37
CYP2D6 P10635 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
ADRA1D P25100 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL139722 0.88 ACHE (0.45) ITGB2ICAM1ITGALP2RX7LMNA
SCHEMBL23189238 0.82 ACHE (0.34) ITGB2ICAM1ITGALP2RX7SLC9A1
SCHEMBL12431218 0.81 P2RX7 (0.35) ITGB2ICAM1ITGALP2RX7EED
SCHEMBL30364084 0.79 AHR (0.39) P2RX7AHRADRA2ACYP2D6ADRA2B
SCHEMBL30364094 0.79 ITGB2 (0.44) ITGB2ICAM1ITGALP2RX7MEN1
SCHEMBL22260971 0.79 P2RX7 (0.35) P2RX7LMNAEEDSUZ12EZH2
SCHEMBL964309 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL945134 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL2830923 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL5543467 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113122061-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 CN claimed
EP-4713327-A1 SPIRO DERIVATIVES AS WRN INHIBITORS Insilico Medicine IP Limited (HK) 2026-03-25 EP disclosed
WO-2024235292-A1 SPIRO DERIVATIVES AS WRN INHIBITORS INSILICO MEDICINE IP LIMITED (CN) 2024-11-21 WO disclosed
US-20240208919-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2024-06-27 US disclosed
US-11787775-B2 Therapeutic compounds and methods of use GENENTECH, INC. (US) 2023-10-17 US disclosed
CN-109563063-B Method for preparing 4-substituted 2, 3-dihydro-1-benzofuran derivatives by cyclisation of 2- (2-diazonium-6-substituted phenyl) ethanoates 拜耳作物科学股份公司 2023-04-28 CN disclosed
CN-109641822-B Process for preparing substituted styrene derivatives 拜耳作物科学股份公司 2022-03-11 CN disclosed
CN-113122061-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 CN disclosed
US-11014917-B2 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2021-05-25 US disclosed
US-20200291004-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-17 US disclosed
US-20190055226-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-02-21 US disclosed
WO-2018029141-A1 METHOD FOR PRODUCING 4-SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN DERIVATIVES BY CYLISATION OF 2-(2-DIAZONIUM-6-SUBSTITUTED PHENYL)ETHANOL SALTS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-02-15 WO disclosed
WO-2018029141-A1 METHOD FOR PRODUCING 4-SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN DERIVATIVES BY CYLISATION OF 2-(2-DIAZONIUM-6-SUBSTITUTED PHENYL)ETHANOL SALTS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-02-15 WO disclosed
WO-2018029140-A1 METHOD FOR PRODUCING SUBSTITUTED STYRENE DERIVATIVES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-02-15 WO disclosed
WO-2016109359-A1 CYCLOPROPYL DIHYDROBENZOFURAN MODULATORS OF MELATONIN RECEPTORS AUSPEX PHARMACEUTICALS, INC. (US) 2016-07-07 WO disclosed
WO-2016109359-A1 CYCLOPROPYL DIHYDROBENZOFURAN MODULATORS OF MELATONIN RECEPTORS AUSPEX PHARMACEUTICALS, INC. (US) 2016-07-07 WO disclosed
CN-101925589-B Process for producing 4-vinyl-2, 3-dihydrobenzofuran SUMITOMO CHEMICAL CO 2013-03-27 CN disclosed
CN-101925589-A Process for producing 4-vinyl-2, 3-dihydrobenzofuran SUMITOMO CHEMICAL CO 2010-12-22 CN disclosed
US-20100298584-A1 PROCESS FOR PRODUCTION OF 4-VINYL-2,3-DIHYDROBENZOFURAN SUMITOMO CHEMICAL COMPANY LIMITED 2010-11-25 US disclosed
EP-2236504-A1 PROCESS FOR PRODUCTION OF 4-VINYL-2,3-DIHYDROBENZOFURAN Sumitomo Chemical Company, Limited (JP) 2010-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055226-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS SLC5A2, SLC5A1, SLC2A2 ITGB2 2470/4885ICAM1 2565/4885ITGAL 2174/4885
US-20200291004-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS SLC5A2, SLC5A1, SLC2A2 ITGB2 2683/4885ICAM1 2690/4885ITGAL 2557/4885
US-20240208919-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, NQO1, PCSK9 ITGB2 3700/4885ICAM1 1822/4885ITGAL 3367/4885
US-11787775-B2 Therapeutic compounds and methods of use VHL, NQO1, PCSK9 ITGB2 3700/4885ICAM1 1822/4885ITGAL 3367/4885
US-11014917-B2 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 ITGB2 2683/4885ICAM1 2690/4885ITGAL 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.